Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)

Phase 2

Completed

Conditions: Leukemia
Lymphoma

Interventions: Drug: Rituximab
Drug: 111In Ibritumomab
Procedure: Planar Scintigraphy Imaging
Drug: 90Y IbritumomabTiuxetan
Drug: Fludarabine
Drug: Bendamustine
Drug: Thymoglobulin
Drug: Tacrolimus
Drug: Methotrexate
Drug: Mycophenolate
Drug: G-CSF
Procedure: Stem Cell Transplantation

First Posted Date: 2011-12-13

Last Posted Date: 2020-05-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT01490723

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Fosaprepitant in Patients Receiving Ifosfamide-based Regimen

Not Applicable

Completed

Conditions: Chemotherapy-induced Nausea and Vomiting
Effects of Chemotherapy
Sarcoma
Adverse Effects of Medical Drugs

Interventions: Drug: Fosaprepitant
Drug: Dexamethasone
Drug: 5HT3 receptor antagonist
Drug: Ifosfamide-based chemotherapy (AI)
Drug: Doxorubicin
Drug: Mesna
Drug: Ifosfamide
Drug: Vincristine

First Posted Date: 2011-12-12

Last Posted Date: 2016-04-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 47

Registration Number: NCT01490060

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

A Study of the HSP90 Inhibitor AUY922

Phase 2

Terminated

Conditions: Lymphoma

Interventions: Drug: AUY922

First Posted Date: 2011-12-05

Last Posted Date: 2017-01-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 21

Registration Number: NCT01485536

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab

Phase 1

Withdrawn

Conditions: Breast Cancer

Interventions: Drug: AMG 479
Drug: Trastuzumab

First Posted Date: 2011-11-24

Last Posted Date: 2016-10-26

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT01479179

Determinants of Multiple Health Risk Behaviors Among Latinos

Conditions: Risk Factors in Latinos
Cancer

Interventions: Behavioral: Questionnaires
Device: Accelerometer
Device: Smart Phone

First Posted Date: 2011-11-24

Last Posted Date: 2019-05-17

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 225

Registration Number: NCT01479257

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Radiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular Lymphoma

Phase 1

Recruiting

Conditions: Ann Arbor Stage I Grade 1 Follicular Lymphoma
Ann Arbor Stage I Grade 2 Follicular Lymphoma
Ann Arbor Stage II Grade 1 Follicular Lymphoma
Ann Arbor Stage II Grade 2 Follicular Lymphoma

Interventions: Other: Clinical Observation
Biological: Rituximab
Radiation: Radiation Therapy

First Posted Date: 2011-11-17

Last Posted Date: 2025-05-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 130

Registration Number: NCT01473628

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Phase 3

Completed

Conditions: Disorder Related to Bone Marrow Transplantation
Leukemia
Transplantation Infection

Interventions: Drug: Fludarabine
Drug: Busulfan
Drug: Clofarabine
Drug: Thymoglobulin
Procedure: Stem Cell Infusion
Drug: Tacrolimus
Drug: Methotrexate

First Posted Date: 2011-11-15

Last Posted Date: 2021-12-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 256

Registration Number: NCT01471444

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Dasatinib

First Posted Date: 2011-11-11

Last Posted Date: 2024-07-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 26

Registration Number: NCT01471106

Locations: 🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies

Phase 1

Completed

Conditions: Lymphoma
Leukemia
Transplantation, Bone Marrow
Transplantation Infection
Blood And Marrow Transplantation

Interventions: Drug: Fludarabine
Drug: Melphalan
Drug: Mycophenolate mofetil
Drug: Tacrolimus
Procedure: Cord Blood Infusion
Drug: Rituximab
Drug: ATG
Drug: Busulfan
Drug: Clofarabine
Radiation: Total Body Irradiation (TBI)

First Posted Date: 2011-11-11

Last Posted Date: 2017-04-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 33

Registration Number: NCT01471067

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Diffuse Intrinsic Pontine Glioma (DIPG) Reirradiation (ReRT)

Phase 1

Completed

Conditions: Brain Cancer

Interventions: Radiation: Radiation Therapy

First Posted Date: 2011-11-10

Last Posted Date: 2022-10-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 12

Registration Number: NCT01469247

Locations: 🇺🇸
Orlando Health, Orlando, Florida, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy